MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001

The Phase III study, MOBILE, is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the long-term efficacy and safety of MDR-001 in approximately 750 patients across 50 ...

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in ...
Nasdaq

Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis

Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis, involving ...
Cure Today

HT-001 Addresses Skin Toxicities in Patients With Cancer

HT-001 demonstrated significant efficacy in reducing skin toxicities from EGFR inhibitors, achieving primary endpoints in all patients. Patients experienced improved quality of life, with 66% ...
Seeking Alpha

Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (MSCL:CA) (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to ...
La Grande Observer

Perfuse Therapeutics Announces Positive Visual, Structural and Safety Data from a Ph1/2a Trial of PER-001 in Glaucoma Patients at the American Glaucoma Society Meeting

Twenty-four-week data from the Ph1/2a trial in glaucoma patients reveals PER-001 to be well-tolerated. Proof of concept is established with both strong functional and structural outcomes Glaucoma ...
Wane

In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I

SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ -- Immusoft of CA, a clinical stage, engineered B cell company, today announced a historic achievement: the safe and well-tolerated re-dosing of a patient with ...
ascopubs.org

RRx-001 Affects Multiple Toxicities in Patients Receiving Concomitant Chemoradiation for Head and Neck Cancers: Observations of the PREVLAR Phase II Trial

PREVLAR was an open-label randomized trial that has been completed and published. Patients were treated with CRT for locally advanced OC or OPC. Arms 1-3 received doses of RRx-001 twice a week ...